Aurobindo Pharma reports better-than-expected 84 percent rise in Q2 profit

Published On 2023-11-13 07:00 GMT | Update On 2023-11-14 11:59 GMT

Hyderabad: India's Aurobindo Pharma Ltd reported a better-than-expected 84.9% rise in second-quarter profit on Thursday, driven by strong sales in core markets Europe and the United States amid stablising drug prices.

Consolidated net profit attributable to owners of the holding company rose to Rs 757 crore ($90.91 million) from 4.09 billion rupees a year earlier. Analysts on an average had expected a profit of Rs 622 crore, according to LSEG data.

The Hyderabad-based company, which makes anti-infectives, anti-diabetic and oncology medicine, said revenue from operations rose 25.7% to Rs 7,219 crore.

U.S. formulation sales, the company's largest segment accounting for 47% of its total revenue, rose 35.7% to Rs 3,385 crore, helped by strong performance in generic injectables unit Eugia. Europe formulation sales increased 16.7% to Rs 1,769 crore, contributing 24.5% to Aurobindo's total revenue.

"This is yet another quarter with highest ever sales, driven by robust performance across the markets, and continued margin expansion, aided by operational leverage and efficiencies," Vice-Chairman Nithyananda Reddy said.

Aurobindo, which derives majority of its revenue through exports, is also into contract manufacturing services and production of active pharmaceutical ingredients ((APIs) crucial to a drug's desired health effect.

API sales rose 20.3% to Rs 1,166 crore.

India's generic drug makers, which draw a significant share of revenue from the United States, are slowly recovering from the effects of eroding prices in the world's largest drug market.

Rivals Sun Pharmaceutical and Dr Reddy's reported better-than-expected second-quarter profits on strong demand from the United States.

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations

2025-07-06 07:00 GMT

Aurobindo Pharma reports better-than-expected 84 percent rise in Q2 profit

Similar News

Indian pharma exports strong at USD 4.9 billion in April-May: Pharmexcil

Expert Panel Approves Post-Marketing Surveillance Study of Eculizumab (Soliris) by AstraZeneca in India

Emcure Pharma incorporates new wholly-owned subsidiary Emcure Wellness

JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations

Govt Panel Proposes Braille Cards, Voice-Enabled QR Codes on Medicine Packs to Aid Visually Impaired

AstraZeneca Imfinzi approved in EU for muscle-invasive bladder cancer

Pfizer's Abrocitinib Phase III Data Accepted by CDSCO Expert Committee

COVID-19 Vaccine and Heart Attack: Biocon Chief, Karnataka CM get into war of words